Your browser doesn't support javascript.
loading
Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer.
Ramalingam, Suresh S; Yang, James C-H; Lee, Chee Khoon; Kurata, Takayasu; Kim, Dong-Wan; John, Thomas; Nogami, Naoyuki; Ohe, Yuichiro; Mann, Helen; Rukazenkov, Yuri; Ghiorghiu, Serban; Stetson, Daniel; Markovets, Aleksandra; Barrett, J Carl; Thress, Kenneth S; Jänne, Pasi A.
Afiliación
  • Ramalingam SS; Suresh S. Ramalingam, Emory University School of Medicine, Winship Cancer Institute, Atlanta, GA; James C.-H. Yang, National Taiwan University and National Taiwan University Cancer Center, Taipei, Taiwan; Chee Khoon Lee, St George Hospital, Sydney, New South Wales; Thomas John, Olivia Newton-John Ca
  • Yang JC; Suresh S. Ramalingam, Emory University School of Medicine, Winship Cancer Institute, Atlanta, GA; James C.-H. Yang, National Taiwan University and National Taiwan University Cancer Center, Taipei, Taiwan; Chee Khoon Lee, St George Hospital, Sydney, New South Wales; Thomas John, Olivia Newton-John Ca
  • Lee CK; Suresh S. Ramalingam, Emory University School of Medicine, Winship Cancer Institute, Atlanta, GA; James C.-H. Yang, National Taiwan University and National Taiwan University Cancer Center, Taipei, Taiwan; Chee Khoon Lee, St George Hospital, Sydney, New South Wales; Thomas John, Olivia Newton-John Ca
  • Kurata T; Suresh S. Ramalingam, Emory University School of Medicine, Winship Cancer Institute, Atlanta, GA; James C.-H. Yang, National Taiwan University and National Taiwan University Cancer Center, Taipei, Taiwan; Chee Khoon Lee, St George Hospital, Sydney, New South Wales; Thomas John, Olivia Newton-John Ca
  • Kim DW; Suresh S. Ramalingam, Emory University School of Medicine, Winship Cancer Institute, Atlanta, GA; James C.-H. Yang, National Taiwan University and National Taiwan University Cancer Center, Taipei, Taiwan; Chee Khoon Lee, St George Hospital, Sydney, New South Wales; Thomas John, Olivia Newton-John Ca
  • John T; Suresh S. Ramalingam, Emory University School of Medicine, Winship Cancer Institute, Atlanta, GA; James C.-H. Yang, National Taiwan University and National Taiwan University Cancer Center, Taipei, Taiwan; Chee Khoon Lee, St George Hospital, Sydney, New South Wales; Thomas John, Olivia Newton-John Ca
  • Nogami N; Suresh S. Ramalingam, Emory University School of Medicine, Winship Cancer Institute, Atlanta, GA; James C.-H. Yang, National Taiwan University and National Taiwan University Cancer Center, Taipei, Taiwan; Chee Khoon Lee, St George Hospital, Sydney, New South Wales; Thomas John, Olivia Newton-John Ca
  • Ohe Y; Suresh S. Ramalingam, Emory University School of Medicine, Winship Cancer Institute, Atlanta, GA; James C.-H. Yang, National Taiwan University and National Taiwan University Cancer Center, Taipei, Taiwan; Chee Khoon Lee, St George Hospital, Sydney, New South Wales; Thomas John, Olivia Newton-John Ca
  • Mann H; Suresh S. Ramalingam, Emory University School of Medicine, Winship Cancer Institute, Atlanta, GA; James C.-H. Yang, National Taiwan University and National Taiwan University Cancer Center, Taipei, Taiwan; Chee Khoon Lee, St George Hospital, Sydney, New South Wales; Thomas John, Olivia Newton-John Ca
  • Rukazenkov Y; Suresh S. Ramalingam, Emory University School of Medicine, Winship Cancer Institute, Atlanta, GA; James C.-H. Yang, National Taiwan University and National Taiwan University Cancer Center, Taipei, Taiwan; Chee Khoon Lee, St George Hospital, Sydney, New South Wales; Thomas John, Olivia Newton-John Ca
  • Ghiorghiu S; Suresh S. Ramalingam, Emory University School of Medicine, Winship Cancer Institute, Atlanta, GA; James C.-H. Yang, National Taiwan University and National Taiwan University Cancer Center, Taipei, Taiwan; Chee Khoon Lee, St George Hospital, Sydney, New South Wales; Thomas John, Olivia Newton-John Ca
  • Stetson D; Suresh S. Ramalingam, Emory University School of Medicine, Winship Cancer Institute, Atlanta, GA; James C.-H. Yang, National Taiwan University and National Taiwan University Cancer Center, Taipei, Taiwan; Chee Khoon Lee, St George Hospital, Sydney, New South Wales; Thomas John, Olivia Newton-John Ca
  • Markovets A; Suresh S. Ramalingam, Emory University School of Medicine, Winship Cancer Institute, Atlanta, GA; James C.-H. Yang, National Taiwan University and National Taiwan University Cancer Center, Taipei, Taiwan; Chee Khoon Lee, St George Hospital, Sydney, New South Wales; Thomas John, Olivia Newton-John Ca
  • Barrett JC; Suresh S. Ramalingam, Emory University School of Medicine, Winship Cancer Institute, Atlanta, GA; James C.-H. Yang, National Taiwan University and National Taiwan University Cancer Center, Taipei, Taiwan; Chee Khoon Lee, St George Hospital, Sydney, New South Wales; Thomas John, Olivia Newton-John Ca
  • Thress KS; Suresh S. Ramalingam, Emory University School of Medicine, Winship Cancer Institute, Atlanta, GA; James C.-H. Yang, National Taiwan University and National Taiwan University Cancer Center, Taipei, Taiwan; Chee Khoon Lee, St George Hospital, Sydney, New South Wales; Thomas John, Olivia Newton-John Ca
  • Jänne PA; Suresh S. Ramalingam, Emory University School of Medicine, Winship Cancer Institute, Atlanta, GA; James C.-H. Yang, National Taiwan University and National Taiwan University Cancer Center, Taipei, Taiwan; Chee Khoon Lee, St George Hospital, Sydney, New South Wales; Thomas John, Olivia Newton-John Ca
J Clin Oncol ; 36(9): 841-849, 2018 03 20.
Article en En | MEDLINE | ID: mdl-28841389
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Piperazinas Tipo de estudio: Prognostic_studies Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Año: 2018 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Piperazinas Tipo de estudio: Prognostic_studies Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Año: 2018 Tipo del documento: Article